Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
← catalyst calendarSponsored by Nuvation Bio Inc. (industry) · NUVB — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
217actual
Sites
77
Countries
Canada, China, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-01 | actual | When the study began enrolling |
| Primary completion | 2025-06-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-06-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non Small Cell Lung Cancer
Intervention
- Drug: Taletrectinib — also filed as DS-6051b, AB-106
Primary outcome
what the primary-completion date above is the date OFObjective response rate (ORR) by independent radiology review committee (IRC)
measured Up to 4 years
Publications
- PMID 40179330 — linked by the registry
- PMID 36877099 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NUVB's whole pipeline · Catalyst calendar · Every registered study · What changed